SPRY · ARS Pharmaceuticals, Inc.

The appointment of Donn Casale as President represents a strategic leadership expansion for ARS Pharmaceuticals, separating the President role from the CEO position previously held jointly by Richard Lowenthal. This move suggests an intent to scale operational and commercial capabilities as the company advances its pipeline — particularly relevant given Casale’s recent tenure as Chief Commercial Officer at Dynavax Technologies, which was acquired by Sanofi in 2026, indicating proven expertise in late-stage development and commercialization within immunology and rare disease spaces. His background at Depomed and Merck further reinforces deep commercial infrastructure experience across diverse therapeutic areas. The compensation package — including a $575,000 base salary, 45% target bonus, and a $6 million equity award — reflects both market-competitive positioning and strong retention incentives, with the equity grant structured to encourage sustained multi-year contribution. Notably, the vesting schedule (25% at one year, then monthly over 36 months) accelerates early retention pressure while maintaining long-term alignment. Casale’s home-based work arrangement in San Jose, CA, also signals operational flexibility, though he remains subject to business travel requirements. The concurrent execution of a Participation Agreement under the Company’s Change in Control and Severance Benefit Plan extends severance protections typical for C-suite officers, albeit with a one-year limitation on accelerated equity vesting in change-in-control scenarios — a provision that may moderate near-term M&A sensitivity. Overall, this is a high-materiality governance and talent signal, directly impacting investor assessment of execution capacity and leadership depth ahead of potential inflection points.